英文【Jefferies】Mineralys Therapeutics（MLYS）：我们高血压支付方调查的关键要点
USA | Biotechnology Key Takeaways From Our Hypertension Payer We surveyed N=20 US payers. Our takeaways: (1) Payer expectations are it
报告摘要
USA | Biotechnology Key Takeaways From Our Hypertension Payer We surveyed N=20 US payers. Our takeaways: (1) Payer expectations are it
核心要点
- 2025 ($)
- 1 (212) 778-8721 | matt.taylor@jefferies.com
报告信息
- 文件全名
- 《英文【Jefferies】Mineralys Therapeutics（MLYS）：我们高血压支付方调查的关键要点-21页.pdf》
- 适合读者
- 核心数据
- would be used 3rd/4th line with a PA to label + step edits, (2) 90% would
- place MLYS on formulary at $5k list price but 60% at $10k, (3) and lorundrostat
- FLOAT (%)
- ADV MM (USD) 76.3%
- 10.74
- 核心议题
常见问题
《英文【Jefferies】Mineralys Therapeutics（MLYS）：我们高血压支付方调查的关键要点》主要包含哪些内容?
USA | Biotechnology Key Takeaways From Our Hypertension Payer We surveyed N=20 US payers. Our takeaways: (1) Payer expectations are it核心数据:would be used 3rd/4th line with a PA to label + step edits, (2) 90% would;place MLYS on formulary at $5k list price but 60% at $10k, (3) and lorundrostat;FLOAT (%)。
这份报告覆盖哪一年、篇幅多大?
覆盖 2025 年,全文约 21。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合战略规划、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了管理咨询等议题。
继续阅读
查看全部 →